Daxor to showcase next-gen portable BVA at ACC.26 session

Daxor (DXR) Corporation announces its participation as an exhibitor at the American College of Cardiology Annual Scientific Session in New Orleans, LA, March 28-30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer. As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient’s total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annual Medicare burden of heart failure readmissions in the United States. “The most expensive patient is the one who comes back,” said Michael Feldschuh, Daxor CEO and President. “Our BVA system replaces clinical guesswork with objective data, allowing teams to optimize fluid management and discharge timing. Peer-reviewed studies demonstrate that BVA-guided care results in a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality, delivering a transformative value proposition that aligns the interests of clinicians, hospital administrators, and payers alike.”